$2.80
0.60[27.27%]
At close: Mar 19
$2.80
0[0.00%]
After Hours: 8:35AM EDT
Anebulo Pharmaceuticals
(NASDAQ:ANEB)Anebulo Pharmaceuticals Stock (NASDAQ:ANEB), Analyst Ratings, Price Targets, Predictions
Anebulo Pharmaceuticals Inc has a consensus price target of $6.5, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Benchmark, HC Wainwright & Co., and Maxim Group on October 3, 2023, September 25, 2023, and September 21, 2023. With an average price target of $6.67 between Benchmark, HC Wainwright & Co., and Maxim Group, there's an implied 138.10% upside for Anebulo Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
HC Wainwright & Co.
Maxim Group
Ladenburg Thalmann
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Anebulo Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 10/03/2023 | Buy Now | 185.71% | Benchmark | Robert Wasserman | → $8 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 09/25/2023 | Buy Now | 114.29% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Reiterates | Buy → Buy | Get Alert |
| 09/21/2023 | Buy Now | 114.29% | Maxim Group | Michael Okunewitch | → $6 | Initiates | → Buy | Get Alert |
| 09/18/2023 | Buy Now | 114.29% | HC Wainwright & Co. | Raghuram Selvaraju | → $6 | Initiates | → Buy | Get Alert |
| 05/18/2023 | Buy Now | 185.71% | Benchmark | Robert Wasserman | → $8 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 02/14/2023 | Buy Now | 185.71% | Benchmark | Robert Wasserman | $10 → $8 | Maintains | Speculative Buy | Get Alert |
| 07/27/2022 | Buy Now | 114.29% | Ladenburg Thalmann | Aydin Huseynov | → $6 | Initiates | → Buy | Get Alert |
| 05/25/2021 | Buy Now | 435.71% | Benchmark | Robert Wasserman | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Anebulo Pharmaceuticals (ANEB)?
The latest price target for Anebulo Pharmaceuticals (NASDAQ: ANEB) was reported by Benchmark on October 3, 2023. The analyst firm set a price target for $8.00 expecting ANEB to rise to within 12 months (a possible 185.71% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Anebulo Pharmaceuticals (ANEB)?
The latest analyst rating for Anebulo Pharmaceuticals (NASDAQ: ANEB) was provided by Benchmark, and Anebulo Pharmaceuticals reiterated their speculative buy rating.
When was the last upgrade for Anebulo Pharmaceuticals (ANEB)?
There is no last upgrade for Anebulo Pharmaceuticals.
When was the last downgrade for Anebulo Pharmaceuticals (ANEB)?
There is no last downgrade for Anebulo Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Anebulo Pharmaceuticals (ANEB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Anebulo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Anebulo Pharmaceuticals was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
Is the Analyst Rating Anebulo Pharmaceuticals (ANEB) correct?
While ratings are subjective and will change, the latest Anebulo Pharmaceuticals (ANEB) rating was a reiterated with a price target of $0.00 to $8.00. The current price Anebulo Pharmaceuticals (ANEB) is trading at is $2.80, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.